LexDanaLexDanabeta
Inventor

Apeng LIANG

Inventor
CN

Overview

3→
Patents
2025–2026
Patent span
Human necessities
Primary field (CPC A)

Patents· 3 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations30%
C07DHeterocyclic compounds30%
A61KPreparations for medical, dental or toiletry purposes20%
C07BGeneral methods of organic chemistry10%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium10%
PatentTitleYear
12,545,681Compound used as RET kinase inhibitor and application thereof202612,509,441Compounds used as kinase inhibitors and application thereof202512,435,0893-oxadiazolyl substituted pyrazolo[1,5,a]pyrimidines for ROS1, NTRK, and ALK mediated diseases2025

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2025–2026Patents assigned to TYK MEDICINES INC (3)· patent assignee history
2025Patents assigned to TYK MEDICINES ZHENGZHOU INC (1)· patent assignee history
2025–2026Based in CN· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
TYK MEDICINES INC32025–2026
TYK MEDICINES ZHENGZHOU INC12025
Locations
LocationPatentsSpan
CN32025–2026